Dr. John Cush RheumNow
3 years 3 months ago
715 women w/ infertility from recurrent implantation failure were randomized to either placebo or prednisone 10 mg/d. Live birth rates were unaffected by pred (37.8% 38.8% w/ PBO; NS), but pred did increase rate of preterm deliveries (11.8% vs 5.5%; P=.04) https://t.co/ey5JDk2Xi5 https://t.co/Rcgphj147r
Dr. John Cush RheumNow
3 years 3 months ago
Treatment and Management of Neuropsychiatric Lupus
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus.
https://t.co/99GXxyIjLl https://t.co/Bor7R2qVtN
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
In appears that the risk of autoimmune disease may be increasing as autoimmune frequency was 1/31 in 1997 and in 2005 the risk was 1/12 in women and 1/20 in men (total: 23.5 million) in the USA.
Dr. John Cush RheumNow
3 years 4 months ago
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/gO9QKbAues https://t.co/gEpuBvDpj5
Dr. John Cush RheumNow
3 years 4 months ago
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd
Dr. John Cush RheumNow
3 years 4 months ago
JAKinib safety takeaways
- avoid in older population 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb
Dr. John Cush RheumNow
3 years 4 months ago
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM
Dr. John Cush RheumNow
3 years 4 months ago
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV
Dr. John Cush RheumNow
3 years 4 months ago
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD
#RNL2023
Dr. John Cush RheumNow
3 years 4 months ago
STOP-RA study on HCQ preventing RA...
HCQ did NOT prevent RA development in pre-RA pts
@RheumNow #RNL2023 https://t.co/uZRqAxWyyo https://t.co/02qUN4Hhrc
Dr. John Cush RheumNow
3 years 4 months ago
Heart to Heart: Cardiovascular Risk in RA
Tune in to hear experts discuss cardiovascular risk assessment, patient education, and the importance of disease control in the latest therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/qfnayksf3q https://t.co/7D62APLK4Z
Dr. John Cush RheumNow
3 years 4 months ago
Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development:
- Obinutuzumab
- Dapirolizumab
- Deucravacitinib
- Litifilimab
- Atacicept
- Telitacicept https://t.co/WZQ3soseDB https://t.co/UdkmFYhbGv
Dr. John Cush RheumNow
3 years 4 months ago
COMING UP NEXT! Join us May 9th for our next Tuesday Night Rheumatology. We'll be focusing on Modern Management of Psoriatic Arthritis
Remission in Psoriatic Arthritis
JAK inhibitors in Psoriasis and PsA
Pregnancy in PsA
https://t.co/8HZZAO1qIX https://t.co/UPGYXqGGu6
